Skip to content

Pasadena Star News

64°F
Friday, May 1st 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biodesix, Inc. - Common Stock (NQ:BDSX)

24.39 +0.08 (+0.33%)
Streaming Delayed Price Updated: 3:30 PM EDT, Aug 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Biodesix, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Biodesix Announces Second Quarter 2026 Results and Highlights
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Participate in Upcoming Investor Conferences
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Announces First Quarter 2026 Results and Highlights
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Recognized as a Top Workplace for Third Consecutive Year
Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development
Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis
A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test’s consistent clinical performance across nodule sizes and patient populations 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Participate in Upcoming Investor Conferences
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Present New Data at Two Major Upcoming Scientific Meetings
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Announces Third Quarter 2025 Results and Highlights
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting
Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays
Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting
One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presented 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Announces One-for-Twenty Reverse Stock Split
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics
Biodesix recently validated Thermo Fisher’s tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Announces Second Quarter 2025 Results and Highlights
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs
Nation’s first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programs 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting
New data from the INSIGHT study demonstrates the VeriStrat Host Immune Classifier (HIC)’s ability to predict overall survival in patients with non-small cell lung cancer treated with immunotherapy 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Biodesix to Participate in Upcoming Investor Conferences
From Biodesix, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.